Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. reported that investment entities affiliated with Insight, each a ten percent owner, executed a series of transactions in Class A and Class B Common Stock. On June 25, 2026, they sold an aggregate 530,982 shares of Class A Common Stock in multiple open-market sales at prices between $71.5879 and $73.1935 per share, all reported as indirect ownership. On the same date, they also converted derivative positions in Class B Common Stock into a matching 530,982 underlying Class A shares, with no remaining derivative positions shown after these conversions. The filing attributes these holdings and transactions to the Insight-affiliated funds referenced in the footnotes.
Hinge Health, Inc. reported proposed sales of Class A common stock by an affiliate under a Form 144 notice. The excerpt lists multiple small dispositions in June 2026, including lots of 779, 2,666, 1,336, 6,336, and 6,309 shares with corresponding cash amounts. The filing also references prior stock conversion and a Class A outstanding count dated 07/03/2018.
Insight Venture Partners reported planned dispositions of Hinge Health Class A Common Stock. The excerpt lists multiple proposed sales executed through Raymond James & Associates as broker, including 06/16/2026 (5,195 shares for $365,518.12) and additional sales on 06/22/2026, 06/23/2026, 06/24/2026, and 06/25/2026 with stated share counts and proceeds.
Hinge Health, Inc. related parties filed notices under Rule 144 reporting proposed sales of Class A Common shares. The excerpt lists several transactions by Insight Venture Partners X, L.P. on 06/16/2026 through 06/25/2026, showing individual sale quantities and gross proceeds for each trade date.
The filings name a broker-dealer (Raymond James & Associates) and reference earlier securities (Series B preferred converted before IPO). These are routine Rule 144 resale notices reporting trades by an institutional holder; timing and cumulative totals beyond the listed rows are not aggregated in the excerpt.
Insight Venture Partners reported multiple proposed sales of Hinge Health, Inc. Class A common stock. The filing lists planned brokered sales on 06/16/2026, 06/22/2026, 06/23/2026, 06/24/2026, and 06/25/2026 with individual share amounts and gross proceeds shown for each date. The transactions are reported on Form 144 and identify Raymond James & Associates as the broker.
Hinge Health, Inc. disclosed that investment entities associated with Insight Venture Partners reported open-market sales of Class A Common Stock. On June 24, 2026, these entities sold a combined 142,311 shares at a reported price of $71.6669 per share through indirect ownership accounts. The Form 4 indicates these particular indirect positions now report zero shares following the transactions, and there are no remaining derivative securities listed in this filing.
Hinge Health, Inc. disclosed that Insight-affiliated investment entities, all reported as ten-percent owners, carried out a series of conversions and open‑market sales involving its Class A and Class B common stock. Over June 22–24, the entities converted a total of 870,104 Class B shares into Class A through derivative conversions coded "C" at a stated conversion price of $0.00 per share.
Across the same dates, they executed 727,793 Class A shares of open‑market sales (code "S") at prices generally around $70–$72 per share, including transactions at $71.6669, $71.1994, $70.8361 and $70.2145. Several non‑derivative transaction lines show zero Class A shares remaining after specific sale blocks, while related derivative entries show that Insight-controlled entities continue to hold indirect positions of Class B common stock in the millions of shares following these conversions.
Hinge Health, Inc. President James Pursley sold 33,000 shares of Class A Common Stock in open-market transactions. The sales occurred on June 22, 2026 across three trades at weighted average prices of $68.93, $69.82 and $70.89 per share.
The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Hinge Health, Inc. large shareholder entities affiliated with Insight reported a combination of share conversions and sales. On June 16, 2026, they converted an aggregate 65,581 shares of Class B Common Stock into Class A Common Stock, then executed open-market sales of 65,581 Class A shares at an average price of $70.3596 per share through indirect holdings noted in the footnotes. Following these transactions, the reported Class A positions in the sale lines were reduced to zero, while significant Class B Common Stock positions remained outstanding as derivative securities.
Hinge Health, Inc. submitted a Form 144 notice concerning certain securities. The filing references 106,729 units tied to Series B Preferred Stock dated 07/03/2018 and lists 06/16/2026 alongside two numeric entries: 51,637,302.00 and 54,655,926. The excerpt also names Raymond James & Associates and includes the phrase Stock Conversion before IPO.